Health

The Russian university team claims to be successful in testing the world’s first Covid-19 vaccine. This is how it was tested on volunteers

Sechenov First Moscow State Medical University began clinical trials of the Sars-Cov-2 vaccine, which causes coronavirus disease, produced by the Russian Gamaleya Institute of Epidemiology and Microbiology on June 18.

A Russian university has claimed that clinical trials of the world’s first coronavirus disease vaccine (Covid-19) in volunteers have been successfully completed. In a statement on its website, Sechenov First Moscow State Medical University said it began clinical trials of the Sars-Cov-2 vaccine, which causes coronavirus disease, on June 18. The vaccine was produced by the Russian Gamaleya Institute of Epidemiology and Microbiology, it said.

The Russian health ministry sanctioned the trial on June 16. The university has said that the first group of volunteers will be discharged on Wednesday and the second on July 20.

This is how clinical trials were conducted:

* The first group of 18 healthy volunteers was vaccinated on June 18.

* The second group of 20 volunteers received the vaccine on June 23 at the Practice Research Center for Interventional Cardiovasology.

* The volunteers were men and women from the age group of 18 to 65 years.

* They receive a lyophilized vaccine or a powder from which a solution for intramuscular injection is prepared.

* Some participants reported headaches and elevated body temperature, however, the university said these symptoms resolved completely within 24 hours of administering the vaccine.

* Participants have been kept in single or double rooms on the Sechenov University campus.

* They will have to spend 28 isolated days after the vaccine injection to protect them from exposure to other infections and after discharge, they will be monitored for an additional 6 months.

* During isolation, volunteers were offered psychological support.

* The Covid-19 vaccine developed by the Gamaleya Institute is also being tested at the Burdenko Military Hospital in Moscow.

* The military hospital is using the liquid form of the medication during the clinical trial.

Back to top button